Key result
hnRNP-A2 T-cell responses in ~28% of RA patients link to active disease and bone erosion.
Observational
Absolute Event Rate: 28% vs 11%
Identification of specific hnRNP-A2 T-cell epitopes associated with disease activity suggests their involvement in the cellular autoimmune pathogenesis of rheumatoid arthritis.
Candidate hnRNP-A2 epitopes merit validation studies in RA; leaves open pathogenicity and therapeutic relevance.
The heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2) has been described as an important autoantigen in rheumatoid arthritis (RA) since it is targeted by autoantibodies, autoreactive T cells, and is aberrantly expressed in synovial cells in patients. To identify hnRNP-A2-specific T-cell epitopes possibly associated with pathogenicity, we used an innovative approach. We first scanned 280 overlapping hnRNP-A2 peptides for binding to the RA-associated class II molecules HLA-DR4 and HLA-DR1, leading to a comprehensive selection of binders. The selected peptides were tested in IFN-gamma-specific ELISPOT assay: PBMC from 18% of RA patients showed a significant IFN-gamma response to hnRNP-A2 peptides, 15% to the overlapping sequences 117-133 and/or 120-133, whereas PBMC from healthy individuals tested negative. We measured proliferative responses to these two peptides in another cohort of patients with RA or osteoarthritis: positive responses were found in 28% of RA, but also in 11% of osteoarthritis patients and these responses could be blocked by anti-MHC class II Ab. Remarkably, the presence of 117/120-133-specific T cells was significantly associated with active disease in RA patients, and bone erosion appeared to be more common in T-cell positive patients. These data suggest involvement of hnRNP-A2 specific cellular autoimmune responses in RA pathogenesis.
No takes yet. Share an insight, caveat, or question.
Trembleau et al. (2010) conducted an observational in rheumatoid arthritis. hnRNP-A2 peptides 117-133 and 120-133 vs. Osteoarthritis patients and healthy individuals was evaluated on Proliferative responses to hnRNP-A2 peptides 117-133 and 120-133. T-cell responses to hnRNP-A2 peptides 117-133 and 120-133 were present in 28% of RA patients versus 11% of OA patients, and were significantly associated with active disease and bone erosion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: